Many colorectal cancer patients initially respond positively to chemotherapy: their tumors shrink and eventually become undetectable. However, an undetectable tumor doesn't equal an absent one. Residual cells may regrow, prompting another round of chemotherapy. Unfortunately, resistance can develop, and patients will see diminished responses despite repeated cycles. In such cases, cancer immunotherapy provides novel methods for those considered incurable by standard approaches.

Bowel cancer immunotherapy operates on two fundamental principles. Firstly, it activates the body's immune system, encouraging it to identify and combat cancer cells. Secondly, it focuses on the precise destruction of cancer cells, sparing healthy ones, often achieved through targeting mechanisms such as antibodies or engineered immune cells.

Even in metastatic cases, the colon cancer immunotherapy success rate may be promising. The response rates to established immunotherapy compounds can range from 40 to 78% for MMRd tumors, with exact outcomes dependent on the specific type of tumor.

At Biotherapy International, we are frequently creating and tweaking new types of immunotherapy for metastatic bowel cancer. Our goal is to achieve minimal residual disease using traditional methods, followed by progressive immunotherapy.

These methods are not yet included in standard care guidelines and are not widely available, so patients with incurable forms of cancer have a chance to recover now.

1

Oncolytic Viruses are human-safe viruses with specific receptors that can penetrate and destroy cancer cells. They also increase the recognition of the tumor by the patient's own immune system.

3

Coley’s Toxin is a mixture of safe bacteria that is used in the production of cancer vaccines. Coley’s Toxin was the first cancer immunotherapy method, which in many cases, achieved significant tumor regression.

All methods are based on sound scientific data, and confirmed through extensive clinical trials involving the successful treatment of thousands of patients.

2

Personalized Cancer Vaccines are made from the patient's cancer cells. Vaccines train the patient's immune system to recognize and destroy malignant cells, just as it does against infectious agents.

4

Allogeneic Targeted Activated Cancer Killer cells (ATACK) are donor killer cells that selectively destroy tumor tissue. ATACKs are powerful and targeted, so they work even when other methods are ineffective.